Greenwich LifeSciences, Inc. Common Stock
GLSI US3968791083
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -30% | -36% | -28% | 4% | 10% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Patel Snehal CEO |
9.88 USD |
3,600 Bought |
35,568 USD |
25/04/2025 | 25/04/2025 |
| Patel Snehal CEO |
8.98 USD |
5,400 Bought |
48,492 USD |
17/04/2025 | 17/04/2025 |
| Patel Snehal CEO |
9.10 USD |
3,600 Bought |
32,760 USD |
07/04/2025 | 07/04/2025 |
| Patel Snehal CEO |
8.73 USD |
5,500 Bought |
48,015 USD |
04/04/2025 | 04/04/2025 |
| Patel Snehal CEO |
12.51 USD |
2,500 Bought |
31,275 USD |
10/01/2025 | 10/01/2025 |
| Patel Snehal CEO |
13.75 USD |
1,800 Bought |
24,750 USD |
06/01/2025 | 07/01/2025 |
| Patel Snehal CEO |
13.31 USD |
1,100 Bought |
14,641 USD |
06/01/2025 | 06/01/2025 |
| Patel Snehal CEO |
12.95 USD |
3,400 Bought |
44,030 USD |
03/01/2025 | 03/01/2025 |
| Patel Snehal CEO |
11.97 USD |
2,000 Bought |
23,940 USD |
02/01/2025 | 02/01/2025 |
| Patel Snehal CEO |
11.36 USD |
2,400 Bought |
27,264 USD |
31/12/2024 | 31/12/2024 |